We confirmed that ERRα in cluster 3 can act as a cofactor of BRD4 to assist SE-promoter loops in SE hijacking, activating glycolysis-related target gene expression, and promoting glycolysis and progression of malignant tumor cells (Fig. 6D), which confers a therapeutic vulnerability to patients in cluster 3. The gene discussed is ESRRA; the disease is neoplasm.